GSK has announced plans to invest $30 billion across the US in research and development and supply chain infrastructure over the next five years (as reported on September 17, 2025), including a new $1.2-billion investment in advanced manufacturing facilities and artificial intelligence (AI) and advanced digital technologies.  

The $1.2-billion investment includes the construction of an additional new biologics flex factory in Upper Merion, Pennsylvania, to deliver new medicines for respiratory disease (COPD, asthma) and cancer (hematological, gynecological, lung and other solid tumors). Construction is planned to begin in 2026. 

The $1.2 billion additionally includes: new AI and advanced digital technology capabilities across GSK’s existing five manufacturing sites in four states (Pennsylvania, North Carolina, Maryland, and Montana); new drug-substance manufacturing capabilities; and new and enhanced device and auto-injector capabilities and assembly. 

The overall $30-billion investment in the US includes capital investments across GSK’s US supply chain, as well as increased investment in R&D—drug discovery and development and clinical trial activity—with the US expected to rank first globally for the number of studies, sites and clinical trials participants conducted by GSK over the next five years (as reported on September 17, 2025).  

GSK has committed new investments of approximately $2 billion in US manufacturing over the last 12 months. In October 2024, the company began construction of a new $800-million facility at GSK’s Marietta, Pennsylvania site, doubling the size and capacity of the site. These new manufacturing investments will create hundreds of highly skilled jobs (in addition to construction jobs), building upon GSK’s approximately 15,000 US workforce. 

Source: GSK